

Neola Medical to Present at Aktiedagarna: Advancing U.S. Market Preparations Following Positive Clinical Safety Results

Neola Medical AB (publ) will deliver a live, on-site presentation at Aktiedagarna in Stockholm on June 10, 2026, at 08:50 CET at Birger Jarl Konferens. CEO Hanna Sjöström will present the company's latest advancements following the positive safety results from Neola Medical's first clinical pilot study in preterm born babies, and provide an update on the company's sharpened strategic focus, U.S. regulatory pathway, and commercial preparations toward market launch. The ongoing rights issue, with subscription period June 3–17, 2026, is intended to finance Neola Medical's continued development, regulatory processes and commercial preparations ahead of market launch.

If unable to attend in Stockholm, the presentation will be streamed online at the following link:

<https://invitepeople.com/public/events/fa647c6285/pages/ea19175b1c>

The presentation will also be accessible for viewing afterward on our company website at www.neolamedical.com

"Neola Medical is entering an important next phase, building on positive safety results from our first clinical pilot study and a sharpened focus on lung collapse detection. At Aktiedagarna, I look forward to presenting our continued preparations toward the U.S. market and how the ongoing rights issue supports this next step," says Hanna Sjöström, CEO of Neola Medical.

About Stora Aktiedagarna

Stora Aktiedagarna in Stockholm is a two-day, action-packed event featuring around 40 company presentations from both large and small businesses. The purpose of Aktiedagarna is to provide investors with objective information about the companies participating in the event. Objective information includes insights delivered directly from company leadership during their presentations, as well as questions posed by moderators to these companies.

For further information, contact:

Hanna Sjöström, CEO

e-mail: hanna.sjostrom@neolamedical.com

About Neola Medical

Neola Medical AB (publ) develops an innovative medical technology device for non-invasive, continuous lung monitoring and real-time alerts of potentially life-threatening lung collapse in preterm born babies. By enabling instant detection, the technology aims to support earlier intervention, improve clinical decision-making, enhance long-term outcomes, and ultimately contribute to saving lives. The patented, cutting-edge technology was developed at Lund University in Sweden and is based on near-infrared light measurements in the lungs. Neola Medical builds on Sweden's longstanding legacy of medical technology innovation and contributions to global health care. Neola Medical was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.

Attachments

[Neola Medical to Present at Aktiedagarna: Advancing U.S. Market Preparations Following Positive Clinical Safety Results](#)